Similar articles for PMID: 31344264

Year	Number of Results
1989	1
1993	1
1995	1
1996	1
2000	1
2001	2
2003	1
2005	1
2007	2
2008	5
2009	5
2010	6
2011	8
2012	9
2013	9
2014	16
2015	18
2016	18
2017	15
2018	33
2019	35
2020	52
2021	32
2022	17
2023	11
2024	0

1

Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.

Xu Q, Li Y, Jing Y, Lv N, Wang L, Li Y, Yu L. Xu Q, et al. Int J Cancer. 2020 Mar 1;146(5):1457-1467. doi: 10.1002/ijc.32593. Epub 2019 Aug 14. Int J Cancer. 2020. PMID: 31344264 Free article.

2

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.

Wang L, Luo J, Chen G, Fang M, Wei X, Li Y, Liu Z, Zhang Y, Gao S, Shen J, Wang X, Gao X, Zhou W, Ma Y, Liu H, Li X, Yang L, Sun K, Yu L. Wang L, et al. Clin Epigenetics. 2020 Sep 1;12(1):132. doi: 10.1186/s13148-020-00923-4. Clin Epigenetics. 2020. PMID: 32873343 Free PMC article. Clinical Trial.

3

Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.

Huang J, Hong M, Zhu Y, Zhao H, Zhang X, Wu Y, Lian Y, Zhao X, Li J, Qian S. Huang J, et al. Leuk Lymphoma. 2018 Nov;59(11):2570-2579. doi: 10.1080/10428194.2018.1443328. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616840

4

[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].

Sun Y, Xu Y, Wu D, Shen H, Yang Z, Qiu H, Chen S, Sun A. Sun Y, et al. Zhonghua Xue Ye Xue Za Zhi. 2015 Dec;36(12):1025-30. doi: 10.3760/cma.j.issn.0253-2727.2015.12.010. Zhonghua Xue Ye Xue Za Zhi. 2015. PMID: 26759106 Free PMC article. Chinese.

5

[Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].

Liu J, Jia JS, Gong LZ, Lu SY, Zhu HH, Huang XJ, Jiang H. Liu J, et al. Zhonghua Xue Ye Xue Za Zhi. 2018 Sep 14;39(9):734-738. doi: 10.3760/cma.j.issn.0253-2727.2018.09.006. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30369183 Free PMC article. Chinese.

6

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.

Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL. Xu J, et al. Medicine (Baltimore). 2018 Sep;97(39):e12102. doi: 10.1097/MD.0000000000012102. Medicine (Baltimore). 2018. PMID: 30278488 Free PMC article.

7

[Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].

Zhang JL, Cao YP, Li JG. Zhang JL, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Apr;27(2):494-503. doi: 10.19746/j.cnki.issn.1009-2137.2019.02.030. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019. PMID: 30998160 Chinese.

8

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.

Hong M, Zhu H, Sun Q, Zhu Y, Miao Y, Yang H, Qiu HR, Li JY, Qian SX. Hong M, et al. Aging (Albany NY). 2020 Apr 1;12(7):5792-5811. doi: 10.18632/aging.102973. Epub 2020 Apr 1. Aging (Albany NY). 2020. PMID: 32238611 Free PMC article.

9

Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.

Lei M, Liu L, Wang Z, Wu D. Lei M, et al. Indian J Cancer. 2019 Apr-Jun;56(2):167-172. doi: 10.4103/ijc.IJC_392_18. Indian J Cancer. 2019. PMID: 31062738 Free article.

10

Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.

Wang H, Wang L, Li C, Wuxiao Z, Shao R, Wang H, Lu Y. Wang H, et al. Oncologist. 2020 Nov;25(11):e1663-e1670. doi: 10.1634/theoncologist.2020-0818. Epub 2020 Sep 21. Oncologist. 2020. PMID: 32845551 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

262 results

Results by year